drugset / Trial / NCT01119417

The Role of Endothelin in the Supine Hypertension of Autonomic Failure

NCT01119417

Phase 1 Withdrawn Vanderbilt University
RandomizedCrossoverSingle-blindOther

Summary

The purpose of this study is to test the hypothesis that endothelin plays a role in the pathogenesis of supine hypertension in pure autonomic failure by increasing vascular resistance. To gauge its contribution to blood pressure regulation, pure autonomic failure and multiple system atrophy patients with supine hypertension will undergo a medication testing with the endothelin blocker, BQ123. We will compare the hemodynamic effects between PAF and MSA patients. Our primary endpoint will be the decrease in blood pressure during the administration of this compound.

Timeline

Start
2010-05
Primary completion
2021-05
Completion
2021-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BQ-123 Peptide 25 unknown Intravenous
Subject BQ-123 Peptide 50 unknown Intravenous
Subject BQ-123 Peptide 100 unknown Intravenous
Subject BQ-123 Peptide 300 unknown Intravenous